FINWIRES · TerminalLIVE
FINWIRES

SHE:002422

6 stories mentioning SHE:002422Updated 11d ago

Every FINWIRES story that references SHE:002422, newest first.

Asia

Sichuan Kelun Pharma Wins Bids for 14 Products Under China's Drug Procurement System; Shares Slide 3%

Sichuan Kelun Pharmaceutical (SHE:002422) won bids for 14 of its products under China's drug procurement system, according to a Monday filing with the Shenzhen bourse.The drugs treat cardiovascular and blood pressure-related problems, prostate cancer, depression and anxiety, fungal infections, and rheumatoid arthritis, among others, the filing said.The company also won bids for its nutritional supplements and oral contraceptives for women.Shares fell 3% during the midday break on Monday.

SHE:002422
Asia

SKB Biopharma's New Indication Application for Breast Cancer Drug Candidate Accepted in China

Sichuan Kelun-Biotech Biopharmaceutical's (HKG:6990, SHE:002422) new indication application for TROP2 ADC sacituzumab tirumotecan was accepted for review by China's National Medical Products Administration.The drug has been developed for the first-line treatment of patients with recurrent or metastatic triple-negative breast cancer, according to a Thursday Hong Kong bourse filing.This is the sixth indication application accepted by the regulator for the product. The acceptance was based on positive results from a phase III registrational study.

HKG:6990SHE:002422
Asia

SKB Biopharma Gets China Nod for Advanced Solid Tumors Drug Trial

Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990, SHE:002422) obtained approval for an investigational new drug application for the clinical trial of SKB565 from China's National Medical Products Administration.The drug is being developed for the treatment of advanced solid tumors, according to a Monday Hong Kong bourse filing.

HKG:6990SHE:002422
Asia

Sichuan Kelun Pharmaceutical Receives AAA Rating from China's Lianhe Credit; Shares Slide 10%

Sichuan Kelun Pharmaceutical (SHE:002422) received an AAA corporate credit rating from Lianhe Credit, according to a Friday filing with the Shenzhen bourse.The outlook on the rating is stable.Lianhe's rating is valid through July 15, 2027.Shares of the pharmaceutical manufacturer fell 10% during afternoon trading on Friday.

SHE:002422
Asia

Kelun Biotech to Present Study Results of Cancer Drugs at American Oncology Meeting

Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) will present the results of its registrational studies on sacituzumab tirumotecan (sac-TMT) and lunbotinib fumarate at the 2026 American Society of Clinical Oncology annual meeting, according to a filing by parent Sichuan Kelun Pharmaceutical (SHE:002422) with the Shenzhen bourse.Its study on its sacituzumab tirumotecan drug versus pembrolizumab for advanced non-small cell lung cancer treatment showed a higher response rate for its sac-TMT against pembrolizumab, the filing said.The company will also present results from its study on lunbotinib, which showed an objective response rate of 87.1% on patients with RET-fusion positive non-small cell lung cancer in patients with prior chemotherapy.

HKG:6990SHE:002422
Asia

Sichuan Kelun Pharmaceutical's Attributable Profit Falls 22% in Q1

Sichuan Kelun Pharmaceutical's (SHE:002422) attributable profit fell 22% to 453.7 million yuan in the first quarter from 584.2 million yuan in the year-ago period, according to a Wednesday filing with the Shenzhen bourse.Earnings per share at the drug manufacturer decreased 22% to 0.29 yuan from 0.37 yuan in the prior-year period.Operating revenue declined 3% year over year to 4.26 billion yuan from 4.39 billion yuan.

SHE:002422

Track with the FINWIRES app suite

FolioX
FolioX
Track SHE:002422 in your portfolio
WheelAI
WheelAI
Analyze SHE:002422 options with the wheel strategy
StockInsider
StockInsider
See market sentiment on SHE:002422